PD-L1
IMMUNE CHECKPOINT
Measures PD-L1 protein expression in tumor and/or immune cells, depending on the assay and indication.
Clinical contextMay inform the use of certain immune checkpoint inhibitors in eligible cancers.
View clinical details
Scoring: Tumor proportion score (TPS) and combined positive score (CPS) are used in different clinical settings. The appropriate assay, score and threshold depend on the cancer type and treatment.
Clinical use: PD-L1 results can inform immunotherapy decisions in selected indications; a result is interpreted with the relevant drug label and clinical context.
FDA assay and scoring examples ↗


